-
French teenager Seixas becomes youngest Fleche Wallonne winner
-
New drugs raise hopes of pancreatic cancer breakthrough
-
South Africa coal delay could cause 32,000 deaths, report says
-
French teenager Seixas becomes youngest winner of La Fleche Wallonne
-
Hezbollah supporters defiant after sons killed fighting Israel
-
EU unblocks 90-bn-euro Ukraine loan after Hungary row
-
Merz says climate policy must not 'endanger' German industry
-
Ziggy Stardust lives on at David Bowie London immersive
-
Thousands of London commuters walk to work in underground strike
-
Boeing reports narrowing loss, points to progress on turnaround
-
Germany halves 2026 growth forecast on Iran war fallout
-
Chinese EVs look to sideline foreign brands at Beijing auto show
-
Russia to block flow of Kazakh oil to German refinery, Berlin says
-
Vietnam, South Korea sign deals on tech, nuclear power
-
EU nears approval of Ukraine loan after Hungary pipeline row
-
Duterte jurisdiction appeal quashed at ICC
-
Three ships targeted in Hormuz, Iran seizes two: monitors, Guards
-
Iran says seized two ships seeking to cross Strait of Hormuz
-
Iran murals project defiance in war with US
-
Ships attacked in Gulf as Trump extends Iran ceasefire
-
Germany set to slash growth forecast due to Mideast war
-
Pakistan's capital holds its breath with US-Iran talks in limbo
-
Groundbreaking Iranian snooker star Vafaei takes on the world
-
Sakib Hussain: IPL quick whose mum sold her jewellery to fund cricket dream
-
US-based Buddhist monks bring peace walk to Sri Lanka
-
NASA unveils new space telescope to give 'atlas of the universe'
-
Trump extends ceasefire, claims Iran 'collapsing financially'
-
The tiny, defiant Nile island caught in the heart of Sudan's war
-
UK inflation jumps as Mideast war propels energy prices
-
Oil falls, stocks mixed as traders weigh outlook after Trump extends truce
-
Anthropic probes unauthorized access to Mythos AI model
-
Stadium that was symbol of NZ post-quake rebuild to hold first match
-
Blazers stun Spurs after Wemby injury, Lakers down Rockets
-
Chinese carmakers aim to build up presence in Europe
-
Maoist landmine legacy haunts India
-
Fiji villagers reject plan for 'Pacific ashtray' in beach paradise
-
India orders school water bells to beat heat
-
Japanese minnows one win from fairytale Champions League title
-
Rugby Australia eyes brighter future as Lions tour brings cash windfall
-
Blazers rally stuns Spurs after Wembanyama injury
-
Young Chinese use AI to launch one-person firms over job anxiety
-
Delicate extraction: Malaysia offers rare earths alternative to China
-
Oil, stocks fall as traders weigh outlook after Trump extends truce
-
Pope to visit prison on final leg of Africa tour
-
US military says key weapons system staying in South Korea
-
India strangles final Maoist bastion as mining looms
-
AI-powered robots offer new hope to German factories
-
Indonesia orangutan forest cleared for 'carbon-neutral' packaging firm
-
PGA Tour mulls pathway back for golfers as LIV plots survival
-
One month phone-free: Young Americans try digital detox
ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology
As H5N1 outbreaks continue to rise globally, the need for robust quality control materials has never been greater. ZeptoMetrix's Influenza A H5N1 Quantitative Stock offers laboratories a comprehensive quality control material that requires RNA extraction, unlike traditional naked RNA products. This novel solution includes three encapsulated H5N1 gene segments within a phage-like particle, ensuring realistic validation of extraction, amplification, and detection steps.
BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows.
"The ongoing H5N1 pandemic highlighted the urgent need for reliable diagnostic tools," said Dr. Karuna Sharma, PhD, Vice President & Chief Scientific Officer of Antylia Diagnostics division. "This launch represents a significant advancement in diagnostic quality control. By encapsulating RNA within a phage-like particle, we enable labs to have confidence in their results at every step. This is not just innovation; it is vital in the fight against H5N1 and other emerging RNA viruses."
NATtrol Influenza A H5N1 Quantitative Stock (Product Code: 0831198) is NATtrol inactivated to enhance stability and provided with precision quantification at 1,000,000 gene copies/mL of each gene segment, verified by digital PCR (dPCR). The ready-to-use 1 mL format integrates seamlessly with ZeptoMetrix's -STQ product line, streamlining workflow adoption.
More information on how to order and additional ZeptoMetrix products can be found at: www.zeptometrix.com
About ZeptoMetrix®
ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.
Product Page: https://www.zeptometrix.com/us/en/nattrol-influenza-a-h5n1-quantitative-stock-1-x-10-ml-15355
Contact Information
Andrew Zenger
Global Product Manager
[email protected]
(716) 715-7417
SOURCE: ZeptoMetrix
View the original press release on ACCESS Newswire
D.Sawyer--AMWN